All Dr Valorie Vanhooren (Co-Founder and CEO of Ona Therapeutics) articles
-
ArticleWhy patient-derived biology matters for ADC discovery
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.